Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: Role in arsenic-induced carcinogenesis

Toxicological Sciences

Volumn 95, Issue 2, 2007, Pages 321-330

  Eblin, Kylee E ^a   Bredfeldt, Tiffany ^b   Buffington, Sarah ^a   Gandolfi, A Jay ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

COX 2; Monomethylarsonous acid; UROtsa

Indexed keywords

ARSENIC; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; METHANEARSONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN TYROSINE KINASE;

AGAR MEDIUM; ANGIOGENESIS; ARTICLE; AUTOPHOSPHORYLATION; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CELL DEATH; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROBLASTOSIS; HUMAN; HUMAN CELL; MITOGENICITY; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGENS; ORGANOMETALLIC COMPOUNDS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33846482728     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfl160     Document Type: Article

References (43)

1. Aposhian, H. V., Gurzau, E. S., Le, X. C., Gurzau, A., Healy, S. M., Lu, X., Ma, M., Yip, L., Zakharyan, R. A., Maiorina, R. M., et al. (2000). Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 13, 693-697.
2. Barchowsky, A., Klei, L. R., Dudek, E. J., Swartz, H. M., and James, P. E. (1999). Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 27, 1405-1412.
3. Bredfeldt, T. G., Jagadish, B., Eblin, K. E., Mash, E. A., and Gandolfi, A. J. (2006). Monomethylarsonous acid induces transformation of human bladder cells. Toxicol. Appl. Pharmacol. 216, 69-79.
4. Castano, E., Dalmau, M., Marti, M., Berrocal, F., Bartrons, R., and Gil, J. (1997). Inhibition of DNA synthesis by aspirin in Swiss 3T3 fibroblasts. J. Pharmacol. Exp. Ther. 280, 366-372.
5. Chiang, G. J., Billmeyer, B. R., Canes, D., Stoffel, J., Moinzadeh, A., Austin, C. A., Kosakowski, M., Rieger-Christ, K. M., Libertino, J. A., and Summerhayes, I. C. (2005). The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU Int. 96, 416-422.
6. Choi, E. M., Kwak, S. J., Kim, Y. M., Ha, K. S., Kim, J. I., Lee, S. W., and Han, J. A. (2005). COX-2 inhibits anoikis by activation of the PI-3K/ Akt pathway in human bladder cancer cells. Exp. Mol. Med. 37, 199-203.
7. Cohen, S. M., and Ellwein, L. B. (1991). Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51, 6493-6505.
8. Drobna, Z., Jaspers, I., Thomas, D. J., and Styblo, M. (2003). Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB 17, 67-69.
9. Eltze, E., Wulfing, C., Von Struensee, D., Piechota, H., Buerger, H., and Hertle, L. (2005). Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int. J. Oncol. 26, 1525-1531.
10. Farivar-Mohseni, H., Kandzari, S. J., Zaslau, S., Riggs, D. R., Jackson, B. J., and McFadden, D.W. (2004). Synergistic effects of COX-1 and -2 inhibition on bladder and prostate cancer in vitro. Am. J. Surg. 188, 505-510.
11. Fosslien, E. (2000). Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30, 3-21.
12. Gao, N., Shen, L., Zhang, Z., Leonard, S. S., He, H., Zhang, X. G., Shi, X., and Jiang, B. H. (2004). Arsenite induces HIF-1 alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol. Cell. Biochem. 255, 33-45.
13. Gee, J., Lee, I. L., Jendiroba, D., Fischer, S. M., Grossman, H. B., and Sabichi, A. L. (2006). Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol. Rep. 15, 471-477.
14. Germolec, D. R., Yoshida, T., Gaido, K., Wilmer, J. L., Simeonova, P. P., Kayama, F., Burleson, F., Dong, W., Lang, R. W., and Luster, M. I. (1996). Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol. 141, 308-318.
15. Gong, Z., Lu, X., Cullen, W. R., and Le, C. (2001). Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J. Anal. At. Spectrom. 16, 1409-1413.
16. Guo, H. R., Chiang, H. S., Hu, H., Lipstitz, S. R., and Monson, R. R. (1997). Arsenic in drinking water and incidence of urinary cancers. Epidemiology 8, 545-550.
17. Hamadeh, H. K., Trouba, K. J., Amin, R. P., Afshari, C. A., and Germolec, D. (2002). Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci. 69, 306-316.
18. Hour, T. C., Pu, Y. S., Lin, C. C., Huang, S. W., Chen, J., Chiu, A. W., Chen, C. J., and Huang, C. Y. (2006). Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer. Anticancer Res. 26, 375-378.
19. Hopenhayan-Rich, C., Biggs, M. L., Fuchs, A., Bergoglio, R., Tello, E. E., Nicolli, H., and Smith, A. H. (1996). Bladder cancer mortality associated with arsenic in drinking water in Argentina [comment][erratum appears in May 1997, Epidemiology 8, 334]. Epidemiology 7, 117-124.
20. Johansson, S. L., and Cohen, S. M. (1997). Epidemiology and etiology of bladder cancer. Semin. Surg. Oncol. 13, 291-298.
21. Klein, R. D., Van Pelt, C. S., Sabichi, A. L., Dela Cerda, J., Fischer, S. M., Furstenberger, G., and Muller-Decker, K. (2005). Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res. 65, 1808-1813.
22. Kosugi, A., Hayashi, F., Liddicoat, D. R., Yasuda, K., Saitoh, S., and Hamaoka, T. (2001). A pivotal role of cysteine 3 of Lck tyrosine kinase for localization to glycolipid-enriched microdomains and T cell activation. Immunol. Lett. 76, 133-138.
23. Lasa, M., Mahtani, K. R., Finch, A., Brewer, G., Saklatvala, J., and Clark, A. R. (2000). Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell. Biol. 20, 4265-4274.
24. Lonn, U., Lonn, S., Nylen, U., Friberg, S., and Stenkvist, B. (1993). Gene amplification detected in carcinoma cells from human urinary bladder washings by the polymerase chain reaction method. Cancer 71, 3605-3610.
25. Loveland, B. E., Johns, T. G., Mackay, I. R., Vailland, F., Wang, Z. X., and Hertzog, P. J. (1992). Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem. Int. 27, 501-510.
26. Mandal, B. K., Ogra, Y., and Suzuki, K. T. (2001). Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas inWest Bengal, India. Chem. Res. Toxicol. 14, 371-378.
27. Marks, F., and Furstenberger, G. (2000). Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. Eur. J. Cancer 36, 314-329.
28. Millar, I. T., Heany, H., Heinekey, D. M., and Fernelius, W. C. (1960). Methyliiodoarsine. Inorg. Synth. 6, 113-115.
29. Mohammed, S. I., Dhawan, D., Abraham, S., Snyder, P. W., Waters, D. J., Craig, B. A., Lu, M., Wu, L., Zheng, R., Stewart, J., et al. (2006). Cyclooxygenase inhibitors in urinary bladder cancer: In vitro and in vivo effects. Mol. Cancer Ther. 5, 329-336.
30. Mohseni, H., Zaslau, S., McFadden, D., Riggs, D. R., Jackson, B. J., and Kandzari, S. (2004). COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. J. Surg. Res. 119, 138-142.
31. Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G., Zoltick, P. W., Biegel, J. A., Hayes, R. L., and Wong, A. J. (1995). Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors 55, 5536-5539.
32. Qu, W., Bortner, C. D., Sakurai, T., Hobson, M. J., and Waalkes, M. P. (2002). Acquisition of apoptotic resistance in arsenic-induced malignant transformation: Role of the JNK signal transduction pathway. Carcinogenesis 23, 151-159.
33. Sens, D. A., Park, S., Gurel, V., Sens, M. A., Garctt, S. H., Somji, S. (2004). Inorganic Cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol. Sci. 79, 56-63.
34. Simeonova, P. P., Wang, S., Hulderman, T., and Luster, M. I. (2002). c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. J. Biol. Chem. 277, 2945-2950.
35. Smith, A. H., Goycolea, M., Haque, R., and Biggs, M. L. (1998). Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am. J. Epidemiol. 147, 660-669.
36. Trouba, K. J., and Germolec, D. C. (2004). Micromolar concentrations of sodium arsenite induce cyclooxygenase-2 expression and stimulate p42/434 mitogen-activated protein kinase phosphorylation in normal human epidermal keratinocytes. Toxicol. Sci. 79, 248-257.
37. Tsai, S. H., Liang, Y. C., Chen, L., Ho, F. M., Hsieh, M. S., and Lin, J. K. (2002). Arsenite stimulates cyclooxygenase-2 expression through activating IκB kinase and nuclear factor-κB in primary and ECV304 endothelial cells. J. Cell. Biochem. 84, 750-758.
38. Vane, J. R., Bakhle, Y. S., and Bolting, R. M. (1998). Cyclooxygenase-1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120.
39. Vega, L., Styblo, M., Patterson, R., Cullen, W., Wang, C., and Germolec, D. (2001). Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol. Appl. Pharmacol. 172, 225-232.
40. Volanti, C., Hendrickx, N., Van Lint, J., Matroule, J.-Y., Agostinis, P., and Piette, J. (2005). Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy. Oncogene 24, 2981-2991.
41. Vollmer, R. T., Humphrey, P. A., Swanson, P. E., Wick, M. R., and Hudson, M. L. (1998). Invasion of the bladder by transitional cell carcinoma: Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 82, 715-723.
42. Wadhwa, P., Goswami, A. K., Joshi, K., and Sharma, S. K. (2005). Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int. Urol. Nephrol. 37, 47-53.
43. Wu, W., Graves, L. M., Jaspers, I., Devlin, R. B., Reed, W., and Samet, J. M. (1999). Activation of EFG receptor signaling pathway in human airway epithelial cells exposed to metal. Am. J. Physiol. 277, L924-L931.